Barrett's esophagus patients have same survival rates as general population

Oct 26, 2009

New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology (ACG) Annual Meeting in San Diego.

Barrett's esophagus is most often diagnosed in people who have long-term (GERD) -- a chronic of acid from the stomach into the lower esophagus. A diagnosis of Barrett's esophagus can be concerning because it increases the risk of developing esophageal cancer.

"Patients who are diagnosed with Barrett's esophagus often fear they will develop esophageal cancer and not survive long," says Ganapathy Prasad, M.D., gastroenterologist, Mayo Clinic and lead author on the study. "Our research examined the of Barrett's esophagus patients from Olmsted County, Minn., over the past three decades, compared to a control group of patients. We wanted to study overall survival, predictors of survival and ultimate cause of death in patients."

In this study of 366 patients, the average patient age was 63 years, with 72 percent men and 18 percent women. All patients with a diagnosis of Barrett's esophagus from 1977 were identified using the Rochester Epidemiology Project resources in Olmsted County and confirmed via review of medical records. Only patients from Olmsted County were selected to reduce referral and selection bias.

Survival data and cause of death was ascertained from of the 366 patients. Overall survival at 10 years after diagnosis was 68 percent. Causes of death included 28 percent from cardiovascular disease, 7 percent from dementia and 7 percent from esophageal cancer. The overall survival of this group was comparable to that of a control sample from the 2000 U.S. census.

"Our population-based study found that Barrett's esophagus patients are at no greater risk of dying than the rest of the population," says Dr. Prasad. "Patients who receive this diagnosis should seek proper treatment and care, but should also know that their odds of dying from are low."

Source: Mayo Clinic (news : web)

Explore further: US OKs first-ever DNA alternative to Pap smear (Update 2)

add to favorites email to friend print save as pdf

Related Stories

DFMO may affect Barrett's esophagus

Nov 16, 2008

Pilot study results suggest that difluoromethylornithine can modulate biomarkers of cell proliferation in patients with Barrett's esophagus and mucosal dysplasia.

Researchers Shed Light on Esophageal Disease

Jun 08, 2009

(PhysOrg.com) -- Canadian Light Source (CLS) staff scientist Luca Quaroni and Dr. Alan Casson from the University of Saskatchewan used the synchrotron's infrared microscope to identify tissue afflicted with ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

9 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

15 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

15 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.